FIELD: pharmacology.
SUBSTANCE: glycosaminoglycan is hyaluronan or a derivative thereof and has a molecular weight of 50-2500 kDa, is treated with an activating agent that is a reaction-limiting reagent. Next, a lipid moiety containing an amino group is introduced into the reaction, lasting from 30 minutes to 3 hours, with the activated glycosaminoglycan for the their covalent binding. The molar amount of the lipid moiety in the reaction is greater than the amount of activator used, which in turn is added in an amount to promote covalent binding of the lipid fragment with 1-7.5% of disaccharide monomer units of the glycosaminoglycan; as well as to the modified glycosaminoglycan obtained by this method, to the drug on its basis and to its application.
EFFECT: improved local delivery of modified hyaluronan through the skin barrier.
27 cl, 20 ex, 17 dwg
Title | Year | Author | Number |
---|---|---|---|
DERMAL FILLER COMPOSITION FOR SMALL WRINKLES TREATING | 2012 |
|
RU2626513C2 |
CARBOHYDRATE CROSS-LINKING AGENT | 2016 |
|
RU2733145C2 |
COMPOSITION OF SKIN FILLER AND TREATMENT METHOD | 2012 |
|
RU2679317C1 |
SKIN FILLERS COMPOSITIONS | 2012 |
|
RU2638713C2 |
INJECTION GEL PRODUCT | 2018 |
|
RU2783125C2 |
TOPICAL USE COMPOSITIONS CONTAINING CROSS-LINKED GLYCOSAMINOGLYCANS | 2017 |
|
RU2748750C2 |
STABILIZED HYALURONIC ACID | 2019 |
|
RU2805502C2 |
OPHTHALMIC PHARMACEUTICAL COMPOSITION | 2016 |
|
RU2734344C2 |
METHOD FOR TRANSPLANTING CELLS FROM DENSE TISSUES | 2011 |
|
RU2574364C2 |
METHOD OF GRAFTING LIVER CELLS TO A SUBJECT WITH LIVER DISEASE OR DYSFUNCTION | 2011 |
|
RU2736955C2 |
Authors
Dates
2017-12-04—Published
2011-05-04—Filed